{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T17:39:48Z","timestamp":1760981988909},"reference-count":19,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2005,11,29]],"date-time":"2005-11-29T00:00:00Z","timestamp":1133222400000},"content-version":"vor","delay-in-days":6329,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatism"],"published-print":{"date-parts":[[1988,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Sera from 28 patients with Lyme disease were tested for the presence of anticardiolipin antibodies (ACLA). Seven serum samples had elevated levels of IgM ACLA, and 4 had elevated levels of IgG ACLA. Higher IgM ACLA positivity tended to be associated with neurologic disease, and IgM ACLA levels correlated with the specific IgM response to the infecting spirochete (<jats:italic>P<\/jats:italic> &lt; 0.01). Absorption experiments indicated that ACLA and antispirochete antibodies are largely separate populations. Thus, ACLA may occur in patients with Lyme disease, particularly in those with neurologic abnormalities, and the production of these antibodies seems to be linked to the specific IgM response.<\/jats:p>","DOI":"10.1002\/art.1780310818","type":"journal-article","created":{"date-parts":[[2007,2,14]],"date-time":"2007-02-14T22:09:59Z","timestamp":1171490999000},"page":"1052-1056","source":"Crossref","is-referenced-by-count":67,"title":["Anticardiolipin antibodies in lyme disease"],"prefix":"10.1002","volume":"31","author":[{"given":"C. G.","family":"Mackworth\u2010Young","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. N.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. C.","family":"Steere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Rizvi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. E.","family":"Malawista","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. R. V.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. E.","family":"Gharavi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,11,29]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-86-6-685"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-197907000-00001"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198303313081301"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/149.5.789"},{"key":"e_1_2_1_6_2","volume-title":"Diagnostic Procedures and Reagents","author":"Harris A","year":"1963"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780220506"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(83)91267-9"},{"key":"e_1_2_1_9_2","first-page":"47","article-title":"Cerebral infarction in systemic lupus: association with anticardiolipin antibodies","volume":"2","author":"Harris EN","year":"1984","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.44.4.281"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0049-0172(87)90003-5"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.45.4.314"},{"key":"e_1_2_1_13_2","volume-title":"Immune reactions of lipids and lipid model membrane, The Antigens","author":"Alving C","year":"1977"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.164.2.614"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198302243080802"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830140609"},{"key":"e_1_2_1_17_2","first-page":"1","article-title":"Cross\u2010reactivity of antiphospholipid antibodies","volume":"16","author":"Harris EN","year":"1985","journal-title":"J Clin Lab Immunol"},{"key":"e_1_2_1_18_2","first-page":"155","article-title":"Affinity purified anticardiolipin and anti\u2010DNA antibodies","volume":"17","author":"Harris EN","year":"1985","journal-title":"J Clin Lab Immunol"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1985.tb02988.x"},{"key":"e_1_2_1_20_2","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0307-742X(21)00606-8","article-title":"Antiphospholipid antibodies","volume":"11","author":"Harris EN","year":"1985","journal-title":"Clin Rheum Dis"}],"container-title":["Arthritis &amp; Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.1780310818","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.1780310818","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T08:21:42Z","timestamp":1700727702000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.1780310818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1988,8]]},"references-count":19,"journal-issue":{"issue":"8","published-print":{"date-parts":[[1988,8]]}},"alternative-id":["10.1002\/art.1780310818"],"URL":"https:\/\/doi.org\/10.1002\/art.1780310818","archive":["Portico"],"relation":{},"ISSN":["0004-3591","1529-0131"],"issn-type":[{"value":"0004-3591","type":"print"},{"value":"1529-0131","type":"electronic"}],"subject":[],"published":{"date-parts":[[1988,8]]}}}